Dr. Frederick H. Wilson
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Harvard Medical School (2007)
- Years since graduation
- 19
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 34
Licensed in Connecticut since 2017, according to the Connecticut Department of Public Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Medical school: Harvard Medical School
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
CT license 56941 (first issued 2017; active) -
Hematology (Internal Medicine) Physician
CT license 56941 (first issued 2017; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Yale-New Haven Hospital New Haven, CT
- Bridgeport Hospital Bridgeport, CT
Medical groups
- Yale University (2,645 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 34
- Services billed
- 83
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 32 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tagrisso (osimertinib mesylate) | 18 |
| Prochlorperazine Maleate Other prescribers in New Haven, CT | 17 |
| Ondansetron Hcl Other prescribers in New Haven, CT | 13 |
| Levothyroxine Sodium Other prescribers in New Haven, CT | 12 |
| Dexamethasone Other prescribers in New Haven, CT | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $250 in research payments for these studies, mostly to the institutions running them.
- A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Eli Lilly and Company · Active, not recruiting · NCT03157128
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.